Ten-year-old XNK Therapeutics experiences rapid growing with own GMP facility
XNK Therapeutics has expanded significantly in the past year and now has access to its own GMP-standard production lab.
“We need to have significantly larger capacity to conduct the larger Phase II studies we’re planning. That capacity isn’t available in Sweden, so we’ve built up our own lab in Flemingsberg,” says Johan Liwing, CEO of XNK Therapeutics.
XNK has grown rapidly in recent years and today the company employs almost 30 people in Novum in Flemingsberg. The new GMP facility, with 350sqm of research laboratory space, gives the company better control over its development chain.
Unique technology
XNK Therapeutics was founded in 2012 and is a pioneer in cell therapy. With a unique platform technology, the company focuses primarily on new forms of cancer treatment. The platform enables new cell-based treatments with autologous NK cells.
A clinical investigator-sponsored Phase II study is already being conducted at Karolinska University Hospital, where XNK’s drug candidate is being combined with Sanofi’s anti-CD38 antibody Sarclisa, Isatuximab, for treatment of the severe cancer form multiple myeloma.
“We’re extremely proud of this smaller Phase II study and now we need to increase production capacity. Myeloma is our main focus area, but when we’ve reached the right capacity, there’ll be one or two more [candidates]. It’s important to create a good width outside the blood cancer area,” says Liwing.
XNK Therapeutics is currently conducting a number of projects, including a “proof of concept” study together with the University of Texas MD Anderson Cancer Center in the field of acute myeloid leukemia (AML).
At the beginning of the year, the company raised approximately SEK 130 million in new capital to drive growth.
“It feels great and above all the fact that it’s not only about capital but also provides the addition of competence and production knowledge through NorthX Biologics. We complement each other in a way that enables good synergies,” says Liwing.
“Flemingsberg is the ideal place for us with immediate proximity to everything we need. It’s also home to research in a world-leading research hub and a proximity to a clinic that really knows NK cells.”
Read more about xnktherapeutics.com.
BioLamina Establishes Operations in Flemingsberg – A Key Player in ATMP Development
As the world’s first and only producer of laminins, the biotechnology company BioLamina has expanded its operations and chosen to establish part of its business in Flemingsberg. Using laminins, a protein that creates an optimal environment for cells to expand and/or differentiate, they are a key player in the development of ATMPs (Advanced Therapy Medicinal Products) in Sweden and globally.
Sally Sow and Turn UP: Winners of the Flemingsberg Science Award IDEA 2024
The music world can be a challenging place, both for organizers trying to reach their audience and for music lovers searching for events that suit their taste. Sally Sow, the winner of the Flemingsberg Science Award IDEA 2024, has developed Turn Up, a platform that simplifies organizing, discovering, and participating in local music events. With a focus on inclusion and accessibility, she aims to create a music scene where everyone feels welcome.
KTH’s Technical Preparatory Year Moves to Flemingsberg – Student Numbers Expected to Double in Autumn 2025
In the autumn of 2025, KTH will relocate its Technical Preparatory Year spots from Södertälje to Flemingsberg, resulting in a significant increase in student numbers at Campus Flemingsberg. By nearly doubling available seats and introducing a new learning center model in collaboration with 3 municipalities, KTH aims to meet the growing demand for technical education in the region.
Drivhuset Stockholm – Where Future Entrepreneurs Take Their First Steps
Imagine a place where young ideas are free to grow, where passion meets ambition, and where the entrepreneurs of tomorrow take their first steps toward greatness. That’s exactly what Drivhuset Stockholm offers – a springboard for the next generation of entrepreneurs. Located on Campus Flemingsberg, we support students every day as they bring their ideas to life and build the skills needed to create real change. Our mission? To provide them with a safe, inspiring environment where they can test and develop their business ideas for real.
OptiCell Solutions – A Key Player in Cell and Gene Therapy Establishes in Flemingsberg
Flemingsberg continues to be a natural choice for knowledge-intensive and innovative businesses. OptiCell Solutions is a company that recently launched its operations at Novum Labs on Campus Flemingsberg. Founded in 2024 by specialists from Karolinska University Hospital and entrepreneurs from the Life Science industry, the company specializes in improving the availability of high-quality target cells for cell and gene therapies, a critical component of the growing ATMP (Advanced Therapy Medicinal Products) sector.
